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Squamous cell carcinomaSchistosomiasis is not known to be associated with any malignant disease other than bladder
cancer. Bladder cancer is still the most common malignant tumor among males in Egypt and
some African and Middle East countries. However, the frequency rate of bladder cancer has
declined signiﬁcantly during the last 25 years. This drop is mainly related to the control of Schis-
tosomiasis. Many studies have elucidated the pathogenic events of Schistosomal-related bladder
cancer with a suggested theory of pathogenesis. Furthermore, the disease presents with a distinct
clinicopathologic proﬁle that is quite different from bladder cancer elsewhere with younger age
at presentation, more male predominance, more invasive stages, and occurrence of squamous
cell carcinoma pathologic subtype. However, recent data suggest that this proﬁle has been dra-
matically changed over the past 25 years leading to minimization of the differences between its
features in Egypt and that in Western countries. Management of muscle-invasive localized dis-
ease is mainly surgery with 5-year survival rates of 30–50%. Although still a debatable issue,
adjuvant and neoadjuvant chemotherapy and radiotherapy have improved treatment outcomes
including survival and bladder preservation rates in most studies. This controversy emphasizes
the need of individualized treatment options based on a prognostic index or other factors that
can deﬁne the higher risk groups where more aggressive therapy is needed. The treatment for
locally advanced and/or metastatic disease has passed through a series of clinical trials since
1970s. These phase II and III trials have included the use of single agent and combination of
chemotherapy and radiotherapy regimens. The current standard of systemic chemotherapy of
generally ﬁt patients is now the gemcitabine–cisplatin combination. In conclusion, a changing
pattern of bladder cancer in Egypt is clearly observed. This is mainly due to the success in
the control of Schistosomiasis. It may also be due to increased exposure to other etiologic fac-
tors that include smoking, pesticides, and/or other causative agents. This change will ultimately
affect disease management.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
It is estimated that over 20% of malignancies worldwide can
be related to infectious agents [1]. Schistosoma haematobium
is a blood ﬂuke, which resides in the system venules and cap-
illaries of the human bladder and other pelvic organs. It is
endemic in Africa and the Middle East including Egypt. First
identiﬁed by Theodor Bilharz in 1851, S. haematobium was
462 H. Khaledinitially implicated in bladder cancer induction by Fergusson
in 1911 [2] and later conﬁrmed in 1994 by the International
Agency for Research on Cancer (IARC) to be carcinogenic
[3]. Schistosomiasis has not known to be implicated in the eti-
ology or pathogenesis of any malignant disease other than
bladder cancer. So, this review will discuss different aspects
of the association between this chronic infection and bladder
cancer in Egypt.Epidemiology, etiology and biologic aspects
Early reports from the Egyptian government in the 1920s indi-
cated that S. haematobium infection rates were as high as
70–80%. Using tartar emetic at that time as treatment had
reduced disease prevalence marginally to about 50% [4]. By
1980, a new effective compound (praziquantel) became avail-
able, and the ministry of health collaborated to design and
implement the Schistosomal Research Project that suggested
the National Schistosomiasis Control Program to begin mass
treatment in schools and high-prevalence villages. With the
success of this project, the prevalence dropped to 6.6% in
1993 and then to 1.9% in 2002 and 1.2% in 2006 [5,6]. This
successful mass treatment was also accompanied by aggressive
public awareness campaigns.
Recently, the 385-Mb genome of S. haematobium was en-
tirely sequenced [7]. This was done using Illumina-based tech-
nology at 74-fold coverage and was also compared to
sequences from related parasites. Genome annotation based
on function, gene ontology, networking, and pathway map-
ping was also demonstrated. It is hoped that this unprece-
dented resource may beneﬁt many fundamental research
areas and help in the design of new disease interventions.
Likewise, and surely with the control of schistosomiasis, the
frequency and incidence rates of bladder cancer consequently
dropped. This drop started to occur with a lag period of 10–
15 years. In late 1980s and early 1990s, bladder cancer ac-
counted for approximately 25–27% of all cancers seen at the
National Cancer Institute of Egypt, the largest and most com-
prehensive cancer center in the country. During the years
2001–2005, this percentage declined signiﬁcantly to account
for approximately 10–15% of all cancers seen at NCI, Egypt
[8]. In more recent years, the data of the population based Na-
tional Cancer registry that includes 5 governorates showed a
frequency rate range of 6–9.2% and an incidence rate range
of 11.6–15.6/100,000 normal population [9]. Thus, it is clear
that changes in the epidemiology of schistosomiasis are re-
ﬂected on the changing epidemiology of bladder cancer.
The mechanisms underlying this association, however, are
largely unknown. Traditionally, it is believed that schistosomia-
sis may cause bladder cancer through bladder irritation,
inﬂammation, and concurrent chronic bacterial infectionsFig. 1 A theory of Schistosomal Bladder Cancer Pathogenesis (chrom[10–12]. The chronic inﬂammatory reaction due to the deposi-
tion of worms and eggs in the tissue consists of macrophages
and neutrophils, which produce endogenous oxygen radicals.
These radicals lead to the formation of carcinogenic N-nitrosa-
mines [13]. Oxygen radicals are also responsible for various
mutations [14], like sister chromatid exchanges [15], and DNA
breaks [16]. Moreover, inﬂammatory cells may contribute to
the activation of polycyclic hydrocarbons and aromatic amines
that further produce speciﬁc carcinogenic metabolites [17].
Using normal epithelial cells in vitro, S. haematobium
parasite extracts were able to induce cancer-like phenotypes
such as loss of p27, increased expression of Bcl-2, proliferation,
apoptosis, migration, invasion, and tumorigenesis [18]. The
same authors also observed carcinogenic and mutagenic ability
of the parasite extract when CD-1 mice normal bladders were
exposed to it. After 40 weeks of intravesical instillation, 70%
of these animals displayed urothelial dysplasia and low grade
intravesical neoplasia. Twenty percent of the dysplastic
bladders presented a mutation in codon 12 of exon 2 of Kras
gene [19].
On the chromosomal level, several reports have elucidated
the chromosomal alterations that characterize schistosomal
bladder cancer cases [20,21]. Using ﬂuorescence in situ hybrid-
ization to detect numerical chromosomal changes in subse-
quent series of cases with various stages of the disease, a
theory of pathogenesis was proposed [22]. This suggested
theory entails the occurrence of both chromosomes Y and 9
alterations for the carcinogenic event to start and then the
development of two genetic pathways for the transition to
invasive stages. The invasive tumors may then develop either
from carcinoma in situ with deletions in the Y and 9 chromo-
somes, or from Ta cases having multiple alterations together
including gain of chromosome 7 or deletions of chromosome
17 (Fig. 1).
Furthermore, studies at the molecular level [23–25] using
different techniques have been done to assess markers of some
oncogenes, tumor suppressor genes, cell cycle regulators, the
tumor’s ability to spread and metastasize, P-glycoprotein
expression, and relation to some oncogenic viruses.
Activation of H-ras oncogene was found [24], and tumor
expression of epidermal growth factor receptor, retinoblas-
toma, and p34 was positive in 64%, 58%, and 48% of the
examined cases, respectively. The p53 proﬁle was evaluated
in urine, serum, and tumor tissue of the same samples. Mutant
forms were found in 20% of urine, 59% of serum, and 40% of
tumor tissue samples [25]. Moreover, the median values of the
soluble adhesion molecules VCAM, ICAM, E-selection, and
the microvessel counts expression angiogenesis were all signif-
icantly higher than normal control levels [25]. It was also ob-
served that telomerase activity is increased in schistosomal
bladder cancer (47%) although a lesser degree than that re-
ported for transitional cell carcinoma in the western world [26].osomal gains and/or deletions). Adapted from Khaled et al. [22].
Table 1 Randomized trials comparing preoperative radiotherapy with cystectomy alone. Adapted from Zaghloul [37].
Study (year) Stage Patients (n) Dose (cGy) Survival rates
Preop. Cyst. Preop. Cyst.
Blackard et al. (1972)a T2–T3 23 22 4500 39 36
Slack et al. (1977) T2–T4 103 131 4500 44 32
Awwad et al. (1979)b T3 36 17 4000–4080 53 19
Anderstorm et al. (1983) T1–T3a 22 22 3200–5400 75 61
Ghoneim et al. (1985) T1–T4 43 49 2000 39 32
Smith et al. (1997) T2–T4 60 64 2000 53 43
Cyst: Cystectomy, Preop: preoperative radiotherapy.
a 3-Year overall survival.
b 2-Year overall survival.
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genes were also reported [27]. Twelve cancer-related genes
(E-cadherin, DAP-Kinase, OMGMT, p14, p15, p16, FHIT,
APC, RASSF 1A, GSTP1, RARB, and p73) were investigated.
Schistosomal bladder cancer had more genes methylated than
non-schistosomal tumors. While methylation of DAP-Kinase
and RAR B was equally distributed between tumors with or
without schistosomal association, methylation of FHIT,
RASSF1 A, E-cadherin, P16, and MGMT tended to be more
common in the parasite-associated tumors. Also, these tumors
demonstrated high median methylation index (0.25) than non-
schistosomal-associated cases. These results suggested that
schistosomal involvement is associated with a greater degree
of epigenetic changes in the bladder epithelium.
Finally, by using Mass ARRAY technology, all 27 schisto-
somal bladder cancer blood tested samples were associated
with HPV-16 DNA. These ﬁndings have lead the authors
[28] to suggest that clinical surveillance of serum and/or urine
sediment indicated both analyzing subjects at high risk of
developing schistosomal bladder cancer and monitoring the
treatment for the disorder.
Lastly, with the anticipation that in the near future with the
eradication of schistosomiasis, there will be a potential rise in
the incidence of bladder cancer related to other risk factors,
and a recent study has found that risk factors may include po-
sitive family history, exposure to pesticides, bladder stones,
consanguinity, recent cystitis, and smoking. These factors seem
to play now more important roles than schistosomiasis in the
development of bladder cancer, especially in Upper Egypt [29].
Clinicopathologic characteristics
Schistosomal bladder cancer presents a distinctive clinicopath-
ologic proﬁle, quite different from that reported from Europe
and North America. In Western countries, bladder cancer is
three times more common in males than in females. Incidence
peaks in the sixth, seventh, and eighth decades of life. Over
90% of the tumors are transitional cell carcinomas. Only
about 25% of patients present with muscle-invasive disease,
i.e., PT2 lesions [30].
Besides higher incidence rates of schistosomal bladder can-
cer compared to the urothelial cell bladder cancer seen in the
West, there are other clinicopathologic differences. However,
with the reduction in schistosomiasis due to control efforts
over the past 40 years, these differences have been minimized.
This is clearly shown by recent studies. In one of these studies[31], more than 9000 patients diagnosed and treated at the Na-
tional Cancer Institute of Egypt between 1970 and 2007 have
been retrospectively analyzed. A signiﬁcant decline of the rela-
tive frequency was observed from 27.6% in the old series to
11.7% in the recent series. Likewise, schistosomal association
dropped from 82.4% to 55.3% with obvious decrease in the
degree of calciﬁcation and viability, the density of ova deposi-
tion, and the occurrence of less associated mucosal changes.
The authors also described an increase in the median age at
presentation from 47.4 years to 60.5 years. There was also a
decrease in the male to female ratio from 5.4 to 3.3. A signif-
icant rise of transitional cell carcinoma from 16% to 65.8%
with a decrease in squamous cell carcinoma from 75.9% to
28.4% was also reported.
In another study [32], data of 2778 patients seen at the NCI,
Egypt, during six calendar years (1980–1983–1990–1994–2001
and 2005) showed also the same results, e.g., patients treated
for bladder cancer in 2005 had a sixfold increased risk of tran-
sitional cell carcinoma vs. squamous cell carcinoma compared
with patients treated in 1980.
A trend for more numbers of superﬁcial (Pa-1) and less
numbers of invasive tumors (P2-4) was also clear when com-
paring two central pathology registries that were studied for
the years 2003–2004 vs. the years 1985–1989. Pa-P1 lesions in-
creased from 7.8% to 35.1%, while P2-4 lesions dropped from
92.2% to 64.9% [33].
Management
Muscle-invasive and locally advanced disease
Treatment for muscle-invasive bladder cancer, which consti-
tutes almost two-thirds of cases in Egypt, remains a challenge.
This is because it aims at local disease control, elimination of
micrometastases, and maintenance of the best possible quality
of life without compromising survival.
Radical cystectomy is still the treatment of choice in most
cases of muscle-invasive bladder cancer worldwide. It is asso-
ciated with a 5-year disease-free survival rate of 30–50%.
The independent prognostic factors that determine the out-
come include tumor stage, grade, and pelvic nodal involve-
ment [34,35]. Sophisticated techniques for urinary diversion
after radical surgery have been developed and are under
study to improve the quality of life and prognosis but even
a continent and ideal diversion cannot substitute for the
original bladder.
Table 2 Nonrandomized postoperative radiotherapy studies for bladder cancer. Adapted from Zaghloul [37].
Study year Patients (n) Tumor type Radiation
dose (cGy)
DFS Local control Distant
metastasis
Cozzarini et al. (1999) 150 TCC 5000 44.6 88.4 NM
El Debawy (2000) 222 TCC, SCC, and adenocarcinomas 5000 75 ± 4 91 ± 2 17 ± 4
Zagloul et al. (2002) 89 TCC, SCC, and adenocarcinomas 5000 64 ± 10 88 ± 9 18 ± 7
Zagloul et al. (2006) 192 Adenocarcinomas 5000 56.7 ± 7.5 97.2 ± 2.8 25.3 ± 4.9
Zagloul et al. (2007) 216 Adenocarcinomas 5000 58 ± 6 94 ± 3 33 ± 6
DFS: Disease-free survival; NM: Not mentioned; SCC: Squamous cell carcinoma; TCC: Transitional cell carcinoma.
464 H. KhaledAfter radical surgery, local recurrence either alone or com-
bined with systemic metastases has been shown to occur in
25–50% of such locally advanced cases [36]. While nonran-
domized trials of preoperative radiotherapy have suggested
improved survival rates, only one of the worldwide published
six randomized preoperative radiotherapy trials (Table 1)
shows survival beneﬁt. On the contrary, most retrospective
reports (Table 2) and the only published randomized trial that
have used postoperative radiotherapy revealed a signiﬁcant
increase in disease-free survival rates [37].
However, postoperative radiotherapy remained unpopular
because of the fear of late gastrointestinal complications. Most
of these pre- and postoperative radiotherapy trials were per-
formed in the 1970s to mid 1990s but with modern radiother-
apy techniques now available, e.g., IMRT (Intensity
Modulated Radiotherapy) and IGRT (Image Guided Radio-
therapy), the possibility of minimizing morbidity and late com-
plications as well as maximizing efﬁciency is surely expected.
In an effort to improve the unsatisfactory survival rates of
radical surgery alone, and in order to avoid the possible late
complications of radiotherapy, many adjuvant and neoadju-
vant systemic chemotherapy trials have been conducted. The
ﬁrst trial was a phase III study randomized using single agent
epidoxorubicin given pre- and postoperatively vs. radical cys-
tectomy alone. One hundred and seventy patients were in-
cluded in both arms, and a higher disease-free survival rate
was observed for those patients who have completed their 6 cy-
cles of chemotherapy [38]. Another study reported from
Mansoura using cisplatin-based neoadjuvant chemotherapy
in 194 patients, however, failed to show a survival beneﬁt [39].
The promising results of using the gemcitabine–cisplatin
combination and the known synergistic effects of gemcitabine
with radiotherapy led to the initiation of subsequent random-
ized trials using both adjuvant and neoadjuvant combining che-
mo- and radiotherapy. In one study, 114 patients were
randomized to either radical cystectomy alone, or to receive 3
cycles of gemcitabine–cisplatin regimen, and tumor response
was then assessed. If a complete remission was achieved, 3 addi-
tional chemotherapy cycles were given followed by radical
radiotherapy. Otherwise, surgery was performed. There was a
trend toward increased survival of patients who have receivedTable 3 Response rates of different combination chemotherapy re
cancer.
No. of patients Eva
Epidx–VCR alternating with VP16 – Ifos. 22
Gemcitabine–Cisplatin (Standard dose) 33
Gemcitabine–Cisplatin (Low dose – prolonged infusion) 54neoadjuvant chemotherapy, but more importantly, bladder
preservation was possible in 22% of patients [38].
In another study, the efﬁcacy of adding adjuvant chemo-
therapy to postoperative radiotherapy was also evaluated in
142 high risk bladder cancer patients. A marginal difference
of improved disease-free survival was observed for those who
have received the combined modality treatment [40].
In addition, many studies have been done to avoid mutilat-
ing surgeries combining transurethral resection, radiation ther-
apy, and systemic chemotherapy. However, no randomized
trials have compared radical cystectomy vs. other approaches.
In such approaches with different modalities, salvage cystec-
tomy is being reserved for patients with incomplete response
or local relapse.
So, the role of adjuvant and/or neoadjuvant chemother-
apy, radiotherapy, or combined modality therapy in conjunc-
tion with local radical surgery is still a debatable issue in the
treatment for muscle-invasive bladder cancer in general and
of schistosomal bladder cancer in particular. Therefore, the
need for developing a prognostic model to deﬁne high risk
group that may beneﬁt of additional therapy is highly indi-
cated and may also explain the controversial date of such
therapy. A prognostic index formed of the 3 known risk
groups, namely P stage, tumor grade, and lymph node affec-
tion was evaluated in a group of 198 bladder cancer cases,
and it may guide for more rationale choice of patients into fu-
ture clinical trials [35].
Metastatic disease
In the absence of any data on tumor chemosensitivity proﬁle
of patients with schistosomal bladder cancer, and starting in
1970s, a series of phase II trials to screen single agent chemo-
therapeutic agents were conducted at the NCI, Egypt. Vari-
ous drugs were tested in groups of 20–25 patients with
advanced and/or metastatic disease [41]. About 5 agents gave
moderate rates (30–60%). It was then logic to try to formu-
late combination(s) of the most active single agents. A com-
bination of the epidoxorubicin–vincristine alternating with
etoposide and ifosfamide thus tried with a response rate of
41% [42].gimens used for management of advanced schistosomal bladder
luable CR PR (CR+ PR) (%)
1 8 (41)
8 10 (54)
5 27 (59)
Schistosomiasis and Cancer in Egypt 465This was followed by another phase II trial of the gemcita-
bine–cisplatin regimen [43]. Given to 37 patients with ad-
vanced disease, an overall response rate of 54% was
achieved. In order to address the cost-beneﬁt value of this
rather expensive regimen, a trial of low dose prolonged infu-
sion gemcitabine combined with cisplatin was applied on a
group of 57 schistosomal bladder cancer cases. With an overall
response rate of 50% and a median survival time of
11.5 months, the data were comparable to that obtained with
the standard dose gemcitabine regimen but with much less
costs [44]. A summary of the results on combination chemo-
therapy regimens in schistosomal bladder cancer is shown in
Table 3.
While many targeted agents have been tried in urothelial
cancer in many centers, the recent report of the expression of
estradiol-like molecules by S. haematobium extract and its
repressive role in inactivation of estrogen receptors in bladder
epithelium [45] could have implications in designing targeted
therapy of schistosomal-associated bladder cancer.
Future prospects
More insights into the pathobiology of schistosomal bladder
cancer and its reﬂection on patients’ management are clearly
needed. Schistosomal bladder cancer in Egypt is a good exam-
ple of a preventable malignant disease. Primary prevention
should continue to eliminate the parasite nationwide. Early
detection is also possible by selective scanning of the high risk
groups, e.g., farmers >20 years of age, using urine cytology.
Researchers should also be urged to the prospects of individu-
alized treatment options based on new biologic prognostic
markers and new targeted therapies. Finally, improving neoad-
juvant and adjuvant measures will not only improve treatment
results and quality of life but also avoid mutilating surgeries
and increase rate of bladder preservation.References
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